Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Epratuzumab is currently being studied in combination with rituximab, for the treatment of
patients with low-grade NHL who failed previous chemotherapy and have never received
rituximab or who received rituximab as a single agent or in combination with chemotherapy as
their last treatment and who demonstrated a partial response or complete response for at
least 12 months.